This is a fully human IgG1 antibody using the same sequences as the therapeutic antibody avelumab. It specifically binds to programmed cell death ligand-1 (PDL1) to obstruct its interaction with its receptors PD1 and B7.1 present on T cells and antigen-presenting cells. By blocking the formation of PD1/PDL1 complex, CD8+ T cell immune response should be enhanced. Avelumab is employed for treating Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma. In vitro studies have demonstrated its ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC), although the contribution of ADCC to the therapeutic effects remains uncertain. Avelumab is an immunotherapeutic and antineoplastic agent belonging to the immune checkpoint blockade cancer therapies group.